Read by QxMD icon Read

Leukemia lymphoma mds myeloma

Jorge J Castillo, Morie A Gertz
In recent years, the survival of patients with plasma cell dyscrasias has improved due to improvements in anticancer and supportive therapy. However, the risk of secondary malignancies has increased, thought to be due to a combination of environmental and disease-related factors, as well as treatment. In the present review, we evaluate the risk of secondary malignancies in patients with monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and Waldenström macroglobulinemia (WM). Patients with MGUS appear to have a higher risk of developing myeloid malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)...
August 22, 2016: Leukemia & Lymphoma
Elif Gülsüm Ümit, Figen Kuloğlu, Ahmet Muzaffer Demir
BACKGROUND: Vancomycin resistant enterococci (VRE) are common pathogens of hospital-acquired infection. Long hospitalization periods, use of broad-spectrum antibiotics and immunosuppression are major risks for VRE colonization. AIMS: We aimed to evaluate patients' characteristics and factors which may contribute to VRE colonization. METHODS: Data of 66 patients with colonization and 112 patients without colonization who have been hospitalized in the Hematology clinic were collected...
August 16, 2016: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
Mounia Elidrissi Errahhali, Manal Elidrissi Errahhali, Redouane Boulouiz, Meryem Ouarzane, Mohammed Bellaoui
BACKGROUND: Hematological malignancies (HM) are a public health problem. The pattern and distribution of diagnosed hematological cancers vary depending on age, sex, geography, and ethnicity suggesting the involvement of genetic and environmental factors for the development of these diseases. To our knowledge, there is no published report on HM in the case of Eastern Morocco. In this report we present for the first time the overall pattern of HM for this region. METHODS: Retrospective descriptive study of patients diagnosed with HM between January 2008 and December 2012 in three centres in Eastern Morocco providing cancer diagnosis, treatment or palliative care services...
2016: BMC Cancer
Bing Liu, Ruihua Mi, Xudong Wei, Lin Chen, Hao Ai, Fangfang Yuan, Qingsong Yin, Yongping Song
OBJECTIVE: To evaluate the value of grand glass opacity(GGO) on CT as a diagnostic sign of pulmonary fungal infection. METHODS: The clinical data of 143 patients treated in department of hematology from January 2007 to June 2015 were analyzed retrospectively, and GGO or other attendant signs were observed. RESULTS: The cases of fungal infection secondary to acute leukemia(AL), myelodysplastic syndromes(MDS), non-Hodgkin's lymphoma(NHL), multiple myeloma(MM), Hodgkin's lymphoma(HL) were 83, 23, 18, 10, 9, respectively, including 23 patients with hematopoietic stem cell transplantation...
January 19, 2016: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Maximilian Stahl, Steven D Gore, Norbert Vey, Thomas Prebet
INTRODUCTION: Epigenetic changes and mutations in epigenetic modifiers characterize and likely drive many cases of acute myeloid leukemia and myelodysplastic syndrome. Development of DNA methyltransferase inhibitors has been most successful in these diseases. While many epigenetic marks are potential targets of cancer therapies, histone deacetylase inhibitors (HDACi) have undergone the most advanced development to date. AREA COVERED: In this review, the authors describe and discuss the biology and the clinical results of HDAC inhibitors in the settings of myeloid malignancies...
2016: Expert Opinion on Investigational Drugs
Yukio Kobayashi
Cumulative evidence suggests that at least some hematologic malignancies are derived from alterations of epigenetic machinery. Next generation sequencing has revealed recurrent mutations of genes related to DNA methylation and histone modification in myelodysplastic syndromes (MDS), acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Both these pathways are targetable and specific inhibitors of their related proteins are currently in development. Among these novel therapies, hypomethylating agents have been approved for MDS, and recently, histone deacetylase inhibitors became available for T-cell lymphoma and multiple myeloma...
October 2015: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Antonella Caivano, Ilaria Laurenzana, Luciana De Luca, Francesco La Rocca, Vittorio Simeon, Stefania Trino, Fiorella D'Auria, Antonio Traficante, Maddalena Maietti, Tiziana Izzo, Giovanni D'Arena, Giovanna Mansueto, Giuseppe Pietrantuono, Luca Laurenti, Pellegrino Musto, Luigi Del Vecchio
Many cell types release extracellular vesicles (EVs), including exosomes, microvesicles (MVs), and apoptotic bodies, which play a role in physiology and diseases. Presence and phenotype of circulating EVs in hematological malignancies (HMs) remain largely unexplored.The aim of this study was to characterize EVs in peripheral blood of HM patients compared to healthy subjects (controls). We isolated serum EVs from patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Waldenstrom's macroglobulinemia (WM), Hodgkin's lymphoma (HL), multiple myeloma (MM), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), myelodysplastic syndromes (MDS), and controls...
December 2015: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
Susan Blumel, Jackie Broadway-Duren
Lenalidomide is an oral immunomodulatory agent approved in relapsed multiple myeloma with dexamethasone, for transfusion-dependent anemia in myelodysplastic syndrome associated with deletion 5q, and in relapsed/progressive mantle cell lymphoma following bortezomib. In recent clinical trials, lenalidomide has shown promising activity in hematologic malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Starting doses and dosing schedules vary by malignancy, with lenalidomide started at a lower dose for CLL than for NHL or multiple myeloma...
July 2014: Journal of the Advanced Practitioner in Oncology
Maria Dalamaga, Gerasimos S Christodoulatos
Higher body mass index and adiposopathy have been associated with increased risk of hematologic malignancies such as leukemia, multiple myeloma, myeloproliferative disorders, Hodgkin's and non-Hodgkin's lymphoma, and myelodysplastic syndromes. Adiponectin is a multimeric protein of the white adipose tissue presenting anti-inflammatory, insulin-sensitizing, anti-atherogenic, cardioprotective, and anti-neoplastic properties. Its anti-neoplastic actions are manifested via two mechanisms: (i) direct action on tumor cells by enhancing receptor-mediated signaling pathways and (ii) indirect action by regulating inflammatory responses, influencing cancer angiogenesis, and modulating insulin sensitivity at the target tissue site...
July 2015: Hormone Molecular Biology and Clinical Investigation
Dandan Liu, Yong Zhang, Suning Chen, Jinlan Pan, Xuefeng He, Jianying Liang, Zixing Chen
This retrospective study was designed to evaluate the clinical and laboratory behaviors of chromosome 3 abnormalities by analyzing the morphological, cytogenetic, and follow-up data from 300 patients of various hematological malignancies with chromosome 3 abnormalities. From the results, trisomy 3, translocation (3q), and del(3) were the abnormal types most frequently observed (>10%) among the chromosome 3 abnormalities. In hematological malignancies, chromosome 3 abnormalities were most frequently seen in the patients with acute myeloid leukemia (AML) (24...
June 2015: Cancer Genetics
Nilanjan Ghosh, Michael R Grunwald, Omotayo Fasan, Manisha Bhutani
Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia. The mode of action includes immunomodulatory, anti-inflammatory, antiangiogenic, and antiproliferative mechanisms. The antitumor effect is a result of direct interference of key pathways in tumor cells and indirect modulation of the tumor microenvironment...
2015: Cancer Management and Research
Shuxu Dong, Shixuan Zhao, Ying Wang, Tianxiang Pang, Yongxin Ru
OBJECTIVE: To investigate the distribution characteristics of blood cells autophagy in hematologic diseases, as well as their possible pathomechanism. METHODS: Retrospective analysis of electron microscopy specimens of 3 277 patients with hematological diseases were performed. The blood cells autophagy was observed by transmission electron microscopy, and its distribution characteristics were analyzed. The pathomechanism of blood cell autophagy was explored in combination with clinical examination and diagnosis...
February 2015: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Michael Keeney, Jaimie G Halley, Daniel D Rhoads, M Qasim Ansari, Steven J Kussick, William J Karlon, Kumudini U Mehta, David M Dorfman, Michael A Linden
CONTEXT: Flow cytometry is often applied to minimal residual disease (MRD) testing in hematolymphoid neoplasia. Because flow-based MRD tests are developed in the laboratory, testing methodologies and lower levels of detection (LODs) are laboratory dependent. OBJECTIVES: To broadly survey flow cytometry laboratories about MRD testing in laboratories, if performed, including indications and reported LODs. DESIGN: Voluntary supplemental questions were sent to the 549 laboratories participating in the College of American Pathologists (CAP) FL3-A Survey (Flow Cytometry-Immunophenotypic Characterization of Leukemia/Lymphoma) in the spring of 2014...
October 2015: Archives of Pathology & Laboratory Medicine
Rashmi Shivani Goswami, Cynthia S Liang, Carlos E Bueso-Ramos, Shimin Hu, Maitrayee Goswami, C Cameron Yin, Gary Lu, L Jeffrey Medeiros, Guilin Tang
It has been controversial if trisomy 15 (+15) as an isolated clonal cytogenetic abnormality in bone marrow (BM) is disease-associated or a benign finding. To answer this question, we retrospectively reviewed our cytogenetic archives and identified 31 patients with isolated +15. Four patients presented with acute myeloid leukemia (AML), +15 was the major clone (56-95% of interphases) in BM and the clonal size of +15 was correlated with blast burden and disease status. For the remaining 27 patients, +15 was a minor clone (3-24% of interphases) in BM...
January 2015: Leukemia Research
Viengneesee Thao, Katy B Kozhimannil, Will Thomas, Ezra Golberstein
No abstract text is available yet for this article.
August 2014: JAMA Internal Medicine
Mohammad Sorowar Hossain, Mohd S Iqbal, Mohiuddin Ahmed Khan, Mohammad Golam Rabbani, Hazera Khatun, Sirajam Munira, M Morshed Zaman Miah, Amin Lutful Kabir, Naima Islam, Tashmim Farhana Dipta, Farzana Rahman, Abdul Mottalib, Salma Afrose, Tasneem Ara, Akhil Ranjan Biswas, Mizanur Rahman, Akm Mustafa Abedin, Mahbubur Rahman, A B M Yunus, Louis W Niessen, Tanvira Afroze Sultana
BACKGROUND: The global burden from cancer is rising, especially as low-income countries like Bangladesh observe rapid aging. So far, there are no comprehensive descriptions reporting diagnosed cancer group that include hematological malignancies in Bangladesh. METHODS: This was a multi-center hospital-based retrospective descriptive study of over 5000 confirmed hematological cancer cases in between January 2008 to December 2012. Morphological typing was carried out using the "French American British" classification system...
2014: BMC Cancer
A Jha
BACKGROUND: Peripheral cytopenias such as anemia, thrombocytopenia, bicytopenia and pancytopenia are common peripheral blood findings in hematological malignances for which bone marrow evaluation is often required. The study was conducted to identify the spectrum of hematological malignancies in association with peripheral cytopenia. METHODS: One year retrospective study was conducted in Tribhuvan University Teaching Hospital. Data of bone marrow examination were retrieved from the archives of the hematology department and analyzed...
September 2013: Journal of Nepal Health Research Council
Masaaki Higashihara
No abstract text is available yet for this article.
March 10, 2014: Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine
Antonio M Risitano, Carmine Selleri
Clonal non-malignant hematological disorders are a heterogeneous group of diseases that are particularly challenging for hematologists. Indeed, most obvious and frequent hematological diseases include a broad spectrum of malignancies, such as leukemias, lymphomas, myeloma, and other myeloproliferative or lymphoproliferative disorders. In recent years, all these diseases have been categorized by the WHO according to a novel classification of myeloid and lymphoid malignancies, which takes in account the outstanding progress in our understanding of molecular defects underlying hematological malignancies...
January 2014: Translational Medicine @ UniSa
Min Shi, Ruobing Xiao, Bruce A Woda, Hongbo Yu
CONTEXT: Hematopathology is a dynamic field that has always been on the frontier of clinical research within the scope of pathology. Several recent developments in hematopathology will likely affect its practice clinically. OBJECTIVE: To review 5 important recent advances in hematopathology: (1) detection and prognostic implication of MYC in diffuse large B-cell lymphomas, (2) determining origin and prognosis through immunoglobulin gene usage in mature B-cell neoplasms, (3)detecting minimal residual disease in multiple myeloma, (4) using genome-wide analysis in myelodysplastic syndromes, and (5) employing whole-genome sequencing in acute myeloid leukemias...
March 2014: Archives of Pathology & Laboratory Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"